Want to see HK:2552 full AI Analyst Report?
Total Valuation
Hua Medicine has a market cap or net worth of HK$2.17B. The enterprise value is HK$1.29B.
Market CapHK$2.17B
Enterprise ValueHK$1.29B
Share Statistics
Hua Medicine has 1,056,605,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,056,605,000
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Hua Medicine’s return on equity (ROE) is 1.07 and return on invested capital (ROIC) is -10.78%.
Return on Equity (ROE)1.07
Return on Assets (ROA)0.73
Return on Invested Capital (ROIC)-10.78%
Return on Capital Employed (ROCE)-0.11
Revenue Per Employee1.13M
Profits Per Employee2.61M
Employee Count424
Asset Turnover0.33
Inventory Turnover1.70
Valuation Ratios
The current PE Ratio of Hua Medicine is ―. Hua Medicine’s PEG ratio is -0.00474.
PE Ratio―
PS Ratio5.69
PB Ratio2.71
Price to FCF-45.79
Price to Operating Cash Flow-59.59
PEG Ratio-0.00474
Income Statement
In the last 12 months, Hua Medicine had revenue of 480.18M and earned 1.08B in profits. Earnings per share was 1.09.
Revenue480.18M
Gross Profit273.10M
Operating Income-141.13M
Pretax Income1.08B
Net Income1.08B
EBITDA-108.66M
Earnings Per Share (EPS)1.09
Cash Flow
In the last 12 months, operating cash flow was -31.85M and capital expenditures -5.34M, giving a free cash flow of -37.19M billion.
Operating Cash Flow-31.85M
Free Cash Flow-37.19M
Free Cash Flow per Share-0.04
Dividends & Yields
Hua Medicine pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.67
52-Week Price Change-42.38%
50-Day Moving Average2.44
200-Day Moving Average2.87
Relative Strength Index (RSI)39.45
Average Volume (3m)1.18M
Important Dates
Hua Medicine upcoming earnings date is Apr 1, 2027, TBA (Confirmed).
Last Earnings DateAug 20, 2026
Next Earnings DateApr 1, 2027
Ex-Dividend Date―
Financial Position
Hua Medicine as a current ratio of 6.17, with Debt / Equity ratio of 35.69%
Current Ratio6.17
Quick Ratio5.59
Debt to Market Cap0.09
Net Debt to EBITDA7.28
Interest Coverage Ratio-17.79
Taxes
In the past 12 months, Hua Medicine has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Hua Medicine EV to EBITDA ratio is -17.88, with an EV/FCF ratio of -32.54.
EV to Sales4.05
EV to EBITDA-17.88
EV to Free Cash Flow-32.54
EV to Operating Cash Flow-37.25
Balance Sheet
Hua Medicine has HK$1.07B in cash and marketable securities with HK$354.20M in debt, giving a net cash position of HK$718.54M billion.
Cash & Marketable SecuritiesHK$1.07B
Total DebtHK$354.20M
Net CashHK$718.54M
Net Cash Per ShareHK$0.68
Tangible Book Value Per ShareHK$1.00
Margins
Gross margin is 60.64%, with operating margin of -29.39%, and net profit margin of 224.44%.
Gross Margin60.64%
Operating Margin-29.39%
Pretax Margin224.44%
Net Profit Margin224.44%
EBITDA Margin-22.63%
EBIT Margin-29.39%
Analyst Forecast
The average price target for Hua Medicine is HK$3.52, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$3.52
Price Target Upside49.15% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast83.49%
EPS Growth Forecast-110.21%